Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 741

The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.

Pathogenesis of non-alcoholic fatty liver disease

Open access
Dowman, J. K., Tomlinson, J.W., Newsome, P.N.·2010·QJM

Abstract

Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of disease ranging from hepatocellular steatosis through steatohepatitis to fibrosis and irreversible cirrhosis. The prevalence of NAFLD has risen rapidly in parallel with the dramatic rise in obesity and diabetes,1,2 and is rapidly becoming the most common cause of liver disease in Western countries.3 Indeed, NAFLD is now recognized to be the aetiology in many cases previously labelled as cryptogenic cirrhosis.4 In Western populations, estimates of NAFLD prevalence vary between 20 and 30%,5,6 rising up to 90% in morbidly obese individuals.7 The more severe, and clinically significant form of NAFLD, non-alcoholic steatohepatitis (NASH) is less common, affecting an estimated 2–3% of the general population,8 and up to 37% of the morbidly obese.7 Of particular concern, and with significant implications for future disease burden, is the increasing prevalence of NAFLD in children and young adults. Studies have reported a 3% prevalence of NAFLD in the general paediatric population, rising to 53% in obese children.9,10 NAFLD has a strong association with type 2 diabetes, with steatosis present in 70% of type 2 diabetics screened with ultrasound,11 and thus it is now recognized to represent the hepatic manifestation of the metabolic syndrome. NAFLD occurs in all ethnic groups although it appears to have a lower prevalence in African-Americans compared with Hispanic and European Americans. This difference remains even after controlling for obesity and insulin resistance (IR)5,12 and may be related to ethnic differences in lipid homeostasis.5 There are no laboratory, imaging or histological findings which can accurately distinguish between NAFLD and alcohol-induced steatosis or steatohepatitis, and the diagnosis can therefore only be made in the absence of a history of significant alcohol intake. Other specific causes of steatosis need to be considered and include metabolic disorders e.g. lipodystrophy and abetalipoproteinaemia, nutritional causes such as rapid weight loss, jejuno-ileal bypass and total parenteral nutrition, and drug-induced. Commonly implicated agents include glucocorticoids, methotrexate, amiodarone, synthetic oestrogens, tamoxifen, diltiazem and highly active anti-retroviral drugs.13–15 Steatosis also commonly occurs in association with hepatitis C, particularly genotype 3, and has an increased prevalence in women with polycystic ovary syndrome, when it is usually associated with IR.16 In the great majority of patients NAFLD develops in association with features of IR and the metabolic syndrome. The metabolic syndrome comprises a cluster of clinical and biochemical features, namely IR, glucose intolerance or diabetes, central obesity, hypertension and dyslipidaemia and is associated with significant cardiovascular morbidity and mortality.17–19 Whilst simple steatosis in the absence of significant fibrosis is considered to be a relatively benign condition,20 the presence of fibrosis predicts both disease progression and liver-related complications over a subsequent 10-year period.21 Decreased survival in this sub-group is due to predominantly cardiovascular causes, although there is a significant increase in liver-related deaths.21 NASH also carries an increased risk of hepatocellular carcinoma (HCC)21 and thus the observation of increased incidence of HCC in type 2 diabetics22 is likely to be due to their high prevalence of NASH.21 In a recent US study, NASH was found to account for at least 13% of overall cases of HCC.23 There are as yet few proven therapies available for patients with NASH, and current strategies are directed towards improving aspects of the metabolic syndrome. Ultimately when such measures fail, liver transplantation remains the only option for patients with end-stage cirrhosis. Although the pathogenesis of NAFLD/NASH is not yet fully understood, much progress has been made in recent years in elucidating the mechanisms of progression from steatosis to more advanced liver inflammation and fibrosis. In this review, we discuss the current understanding of NAFLD pathogenesis, and anticipate that such knowledge will eventually translate into the development of novel treatment strategies for this increasingly important disease. Initial theories for the pathogenesis of NASH were based on a ‘2-hit hypothesis’ (Figure 1a). The ‘first hit’, hepatic triglyceride accumulation, or steatosis, increases susceptibility of the liver to injury mediated by ‘second hits’, such as inflammatory cytokines/adipokines, mitochondrial dysfunction and oxidative stress, which in turn lead to steatohepatitis and/or fibrosis.24,25 However, there is increasing recognition of the role that free fatty acids (FFA) play in directly promoting liver injury, which has led to modification of this theory (Figure 1b). In obesity and IR there is an increased influx of FFA to the liver. These FFA either undergo β-oxidation or are esterified with glycerol to

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/qjmed/hcp158

Cites

140 of 140 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 140 references

Cited by

See all 741

Metadata

Authors
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N.
Venue
QJM
Published
2009-11-13
Volume
103
Issue
2
Pages
71-83
ISSN
  • 0033-5622 (ISSN-L)
  • 1460-2725
  • 1460-2393
OpenAlex
W2165820110
Cited by
741
References
140
FWCI
11.93
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pathogenesis of non-alcoholic fatty liver disease. https://app.cochat.ai/papers/10.1093/qjmed/hcp158
The paper
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2010). Pathogenesis of non-alcoholic fatty liver disease. QJM. https://doi.org/10.1093/qjmed/hcp158

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.